Prostate Cancer - Results from #400

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men with Biochemically Recurrent Prostate Cancer August 22, 2024

Radiotherapy and immunology August 22, 2024

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. August 22, 2024

Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake. August 22, 2024

PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer. August 22, 2024

Epigenome-wide association study of prostate cancer in African American men identified differentially methylated genes. August 22, 2024

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. August 22, 2024

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. August 21, 2024

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial). August 21, 2024

Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare. August 21, 2024

Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy. August 21, 2024

Clinical decision making in prostate cancer care-evaluation of EAU-guidelines use and novel decision support software. August 21, 2024

Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer. August 21, 2024

Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together? August 20, 2024

Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer. August 20, 2024

Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No. August 20, 2024

Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis. August 20, 2024

Evaluation of prostate cancer detection using micro-ultrasound versus MRI through co-registration to whole-mount pathology. August 20, 2024

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate. August 19, 2024

Evaluating the added value of concurrent contrast-enhanced diagnostic CT for PSMA-PET/CT Interpretation. August 19, 2024

Page 21 of 1437